Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity

A Rehman, S Saidullah, M Asad, UR Gondal… - Clinical …, 2024 - Wiley Online Library
Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …
被引用次数：4 相关文章

Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity

A Rehman, S Saidullah, M Asad… - Clinical …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity

A Rehman, S Saidullah, M Asad, UR Gondal… - Clinical …, 2024 - ncbi.nlm.nih.gov
Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.

A Rehman, S Saidullah, M Asad, UR Gondal… - Clinical …, 2024 - europepmc.org
Background Semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …